EP4701636A1 - Behandlung von psoriasis unter verwendung eines kleinmoleküligen hemmers des tumornekrosefaktors alpha - Google Patents

Behandlung von psoriasis unter verwendung eines kleinmoleküligen hemmers des tumornekrosefaktors alpha

Info

Publication number
EP4701636A1
EP4701636A1 EP24722208.6A EP24722208A EP4701636A1 EP 4701636 A1 EP4701636 A1 EP 4701636A1 EP 24722208 A EP24722208 A EP 24722208A EP 4701636 A1 EP4701636 A1 EP 4701636A1
Authority
EP
European Patent Office
Prior art keywords
compound
psoriasis
subject
score
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24722208.6A
Other languages
English (en)
French (fr)
Inventor
Ohn CHOW
Nassr NASSR
Mai Anh NGUYEN
Laurent Perrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of EP4701636A1 publication Critical patent/EP4701636A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP24722208.6A 2023-04-26 2024-04-25 Behandlung von psoriasis unter verwendung eines kleinmoleküligen hemmers des tumornekrosefaktors alpha Pending EP4701636A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP23315116 2023-04-26
US202363539764P 2023-09-21 2023-09-21
PCT/EP2024/061394 WO2024223740A1 (en) 2023-04-26 2024-04-25 Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha

Publications (1)

Publication Number Publication Date
EP4701636A1 true EP4701636A1 (de) 2026-03-04

Family

ID=90922708

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24722208.6A Pending EP4701636A1 (de) 2023-04-26 2024-04-25 Behandlung von psoriasis unter verwendung eines kleinmoleküligen hemmers des tumornekrosefaktors alpha

Country Status (8)

Country Link
EP (1) EP4701636A1 (de)
KR (1) KR20260004440A (de)
CN (1) CN121038791A (de)
AU (1) AU2024264495A1 (de)
IL (1) IL324175A (de)
MX (1) MX2025012780A (de)
TW (1) TW202508596A (de)
WO (1) WO2024223740A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120418259A (zh) 2022-11-23 2025-08-01 弗沃德医疗公司 TNFα活性的调节剂
WO2025038927A1 (en) 2023-08-16 2025-02-20 Raythera, Inc. Modulators of tnf alpha activity and uses thereof
TW202547476A (zh) 2024-04-03 2025-12-16 美商弗沃德醫療公司 TNF-α活性調節劑
WO2025247401A1 (zh) * 2024-05-31 2025-12-04 海思科医药集团股份有限公司 一种稠合杂环衍生物及其在医药上的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
PE20170693A1 (es) 2014-10-03 2017-06-13 Ucb Biopharma Sprl Derivados de imidazol pentaciclicos fusionados
PT3939980T (pt) 2017-04-25 2023-08-07 UCB Biopharma SRL Processo de preparação de derivados de imidazol pentacíclico fundido e utilizações dos mesmos como moduladores da atividade do tnf

Also Published As

Publication number Publication date
WO2024223740A1 (en) 2024-10-31
AU2024264495A1 (en) 2025-12-11
KR20260004440A (ko) 2026-01-08
MX2025012780A (es) 2025-12-01
IL324175A (en) 2025-12-01
CN121038791A (zh) 2025-11-28
TW202508596A (zh) 2025-03-01

Similar Documents

Publication Publication Date Title
AU2024264495A1 (en) Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha
US20240366585A1 (en) Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)
US11660302B2 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
AU2014249534B2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
KR20220163986A (ko) 브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법
TW202345799A (zh) Ｔｙｋ２抑制劑及其用途
EP4333877A1 (de) Verfahren zur behandlung von autoimmunerkrankungen mit ilt7-bindenden proteinen
TW202421141A (zh) 用於多發性硬化症及重症肌無力之治療性酪胺酸激酶抑制劑
UA127744C2 (uk) Спосіб лікування та профілактики розсіяного склерозу з застосуванням сполуки заміщеного амінопіримідину (варіанти)
JP2024535431A (ja) シェーグレン症候群の治療及び予防におけるｃｄ４０ｌ特異的ｔｎ３由来足場
WO2024152001A1 (en) Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome
US20250339442A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
US20240238290A1 (en) Use of complement factor d inhibitor for treatment of generalized myasthenia gravis
WO2021127359A1 (en) Use of lemborexant for treating insomnia
WO2024126431A1 (en) Anti-ilt7 binding agents for the treatment and prevention of myositis
US20250144077A1 (en) Dosage regimen for thrombopoietin receptor agonist
CN118973583A (zh) Tyk2抑制剂及其用途
CN117561076A (zh) 使用ilt7结合蛋白治疗自体免疫病症的方法
EP4704843A1 (de) Dosierungsplan von orismusilast
HK1232801B (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
HK1232801A1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40131350

Country of ref document: HK